Vaccinex logo
Vaccinex Reports First Quarter 2024 Financial Results and Provides Corporate Update
15. Mai 2024 18:00 ET | Vaccinex, Inc.
Last patient last visit in SIGNAL-AD Phase 2a study of pepinemab treatment for Alzheimer’s Disease in early June 2024. $8.2 million of new financing in Q1.
Vaccinex logo
Vaccinex Reports 2023 Financial Results and Provides Corporate Update
02. April 2024 08:30 ET | Vaccinex, Inc.
Expect Topline Data for Randomized SIGNAL-AD Study of Pepinemab for Alzheimer’s Disease in Q3 2024. $17.9 million of new financing in Q4 2023 and Q1 2024.
Vaccinex logo
Vaccinex, Inc. Announces $1.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
27. März 2024 08:30 ET | Vaccinex, Inc.
ROCHESTER, N.Y., March 27, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company pioneering a differentiated approach to...
Vaccinex logo
Vaccinex Announces Multiple New Agreements for Access to ActivMAb® Antigen Virus Technology
21. Februar 2024 08:00 ET | Vaccinex, Inc.
Eight new antibody discovery agreements incorporate Vaccinex’s powerful ActivMAb® Drug Discovery Platform ActivMab® platform enables the discovery and development of high value antibodies against...
Vaccinex logo
Vaccinex, Inc. Announces Reverse Stock Split
15. Februar 2024 08:00 ET | Vaccinex, Inc.
ROCHESTER, N.Y., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc., (NASDAQ: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease...
Vaccinex logo
Vaccinex Announces Pricing of $3.7 Million PIPE Financing
07. Februar 2024 08:00 ET | Vaccinex, Inc.
ROCHESTER, N.Y., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company pioneering a differentiated approach to...
Vaccinex logo
Nasdaq Grants Vaccinex Extension Until March 4, 2024 to Regain Compliance with Listing Rule
04. Dezember 2023 08:00 ET | Vaccinex, Inc.
Company Has Reassured Nasdaq of Actions It Plans to Take to Meet Minimum Bid Price Requirement Randomized Phase 2 Study in Alzheimer’s Disease on Schedule to Complete Treatment in June 2024 ...
Vaccinex logo
Vaccinex Reports Third Quarter 2023 Financial Results and Provides Corporate Update
13. November 2023 08:00 ET | Vaccinex, Inc.
Phase 1/2a Randomized SIGNAL-AD Study of Pepinemab in Alzheimer’s Disease Achieves Full Accrual Expect to Complete 12-months treatment in June, 2024 Company raised over $10 million of new...
Vaccinex logo
Vaccinex Reports Clinical Benefit in Interim Analyses from two Phase 2 Studies of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer’s Annual Meeting
31. Oktober 2023 09:00 ET | Vaccinex, Inc.
ROCHESTER, N.Y., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company, will be reporting novel findings for its lead product, pepinemab, in two...
Vaccinex logo
Vaccinex Reports Positive Effect of Pepinemab Treatment on New Biomarker of Brain Inflammation in Neurodegenerative Diseases
26. Oktober 2023 09:30 ET | Vaccinex, Inc.
ROCHESTER, N.Y., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company, today reports novel findings for its lead product, pepinemab, in a...